Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARAVONE vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Treatment of amyotrophic lateral sclerosis (ALS)
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
Terminal elimination half-life is 4.5-6 hours. In patients with moderate hepatic impairment, half-life may be prolonged up to 9 hours. No significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Edaravone is metabolized primarily via glucuronidation by UGT1A6, UGT1A9, and UGT2B7, and also undergoes sulfation. It is not significantly metabolized by CYP450 enzymes.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Primarily renal excretion as unchanged drug and metabolites (approximately 60-70% unchanged edaravone in urine). Minor fecal elimination (<10%).
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 90-92% bound to plasma proteins, primarily to albumin.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
Volume of distribution is approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. Predominantly distributes in extracellular fluid.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral bioavailability is approximately 50-60% due to first-pass metabolism. For the intravenous formulation (approved), bioavailability is 100% by definition.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
No dose adjustment required for GFR ≥30 m L/min/1.73 m². Safety and efficacy not established for GFR <30 m L/min/1.73 m²; use with caution.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
No specific guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to lack of data.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Not approved for use in pediatric patients; safety and efficacy not established.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
No specific dose adjustment required; pharmacokinetic studies show no significant differences in elderly patients. Monitor renal function as age-related decline may occur.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
None.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Hypersensitivity reactions (e.g., urticaria, dyspnea) have been reported; discontinue if severe.,Monitor for sulfite sensitivity in patients with asthma (contains sodium bisulfite).,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Use with caution in moderate to severe hepatic impairment.
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Hypersensitivity to edaravone or any of its excipients.,Severe renal impairment (Cr Cl <30 m L/min).
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
No significant food interactions reported. No dietary restrictions known.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal malformations (e.g., skeletal abnormalities) at doses below the human equivalent. Risk cannot be excluded for all trimesters.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
No data on edaravone excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Use only if potential benefit justifies risk to fetus; consider alternative treatments if pregnancy occurs.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
Monitor for hypersensitivity reactions, including anaphylaxis; edema and gait disturbance are common adverse effects. Avoid use in patients with severe hepatic impairment. Administer intravenous infusion over 60 minutes; do not mix with other medications in the same bag. Renal function monitoring recommended.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
This medication is used to slow the progression of ALS symptoms.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,You may experience swelling in the legs or difficulty walking; notify your doctor if these become severe.,Do not drive or operate heavy machinery until you know how the medication affects you.,Keep all appointments for infusion and blood tests to monitor your kidney function.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARAVONE vs CELEXA, answered by our medical review team.
EDARAVONE is a Amyotrophic Lateral Sclerosis Agent that works by Edaravone is a free radical scavenger that reduces oxidative stress by trapping hydroxyl radicals, peroxynitrite, and other reactive oxygen species, thereby protecting neuronal cells from oxidative damage.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARAVONE and CELEXA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARAVONE is: 60 mg intravenously over 60 minutes once daily for 14 days, followed by a 14-day drug-free period, then 60 mg intravenously over 60 minutes once daily for 14 days.. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARAVONE and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARAVONE is classified as Category C. Edaravone is not recommended during pregnancy due to lack of adequate human data. In animal studies, intravenous administration during organogenesis resulted in increased fetal mal. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.